Lower-dose prescriptions in the post-marketing situation and the influencing factors thereon

Abstract

The dosage of pharmaceuticals is determined through the process of clinical development and approval review based on clinical trial results; however, the information obtained from clinical trials before approval is limited. Some pharmaceutical products are used at doses lower than those approved for post-marketing use. The aim of this study was to reveal the actual state of lower-dose prescriptions for post-marketing clinical use of pharmaceuticals. We investigated the factors related to the deviation based on therapeutic area, detailed statement of the approved dosage, clinical data package, and post-marketing requirement. Among the new molecular entities approved in Japan between January 2005 and December 2014, we identified products that are orally administered and have the same daily dose for different indications, if any. For these products, we collected information on the actual daily dose from the medical information databases of Medical Data Vision Co., LTD. and Jamm-Net Co., LTD. Products whose dose was lower than the approved dose (maintenance dose excluding the initial dose) in � 30% prescriptions in 2015 were defined here as "lower-dose prescription drugs." We identified 27 lower-dose prescription drugs out of 113 products investigated. The results of the multivariate analysis revealed that factors related to the Anatomical Therapeutic Chemical classification and the detailed statement of the approved dosage significantly influenced the occurrence of lower-dose prescription, whereas the factors related to clinical data package and post-marketing requirements did not. These results suggest the limitation in determining an optimal dosage for the actual clinical use of a drug based on the information obtained from clinical trials conducted before approval, emphasizing the importance of reexamining the optimal dosage that is applicable to a greater number of patients after marketing, if necessary. We believe that the utilization of real-world data could be of help in this regard.

The impacts of undetected nonadherence in phase II, III and post‐marketing clinical trials: An overview

“…An intriguing quantitative insight into the potential impact of nonadherence on dose response comes from the observation of drugs undergoing post‐marketing dose reduction. A recent study by Ogata et al 36 further supports the conclusions of two earlier papers, indicating that one in five drugs on the market is prescribed at a dosage at least 50% higher than required.…”

The influence of ACE inhibitors and ARBs on hospital length of stay and survival in people with COVID-19

“…Both ACEi and ARB medication doses were recorded and categorised into low and high dose (low dose = as per the British National Formulary initial dose or below maintenance dose; high dose = equal or greater than maintenance dose). Doses for hypertension in adults 18-75 years old were used if the British National Formulary (BNF) stated more than one indication or specific age group for a drug [25,26]. Sacubitril-valsartan was classified as an ARB.…”

Italian Real-World Analysis of a Tyrosine Kinase Inhibitor Administration as First- or Second-Line of Therapy in Patients with Chronic Myeloid Leukemia

“…The regulatory approved dosage regimens of drugs are usually derived from clinical trials results, however, post-marketing dosing variations are often observed in clinical practice. 19 …”